Olcay Aksoy, MD
Cardiovascular Disease · Los Angeles, CANPI 1881748630
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (55.0%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Edwards Lifesciences at 51.6% of the total. Reporting peaked in 2023 at $30,701 and has fallen 79.6% since, to $6,274 in 2025. Among cardiovascular disease clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 348 payments — averaging $165.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$30K
- Siemens Medical Solutions USA, Inc.$11K
- GE HealthCare$7K
- Medtronic$3K
- Abbott$3K
- Boston Scientific$709
- plus $3K from 13 others
Across 14 payments — averaging $13,240 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$111K
- Amgen$41K
- Cardiovascular Systems Inc.$33K
- Daiichi Sankyo Inc.$493
What the payments were for
- Consulting fees$5,2259%
- Speaking & faculty fees$4,2007%
- Grants$2250%
- Travel & lodging$31,70155%
- Food & beverage$16,28528%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 187 | $29,729 |
| Siemens Medical Solutions USA, Inc. | 21 | $10,646 |
| GE HealthCare | 1 | $7,267 |
| Medtronic(2 entities) | 46 | $3,495 |
| Abbott | 34 | $2,988 |
| Boston Scientific | 12 | $709 |
| Shockwave Medical, Inc | 10 | $684 |
| Abiomed | 14 | $624 |
| Philips North America LLC | 3 | $406 |
| Penumbra, Inc. | 2 | $384 |
| Heartflow, Inc. | 2 | $283 |
| Cardiva Medical, Inc. | 8 | $165 |
| Johnson & Johnson | 1 | $123 |
| Cardiac Dimensions, Inc. | 1 | $32 |
| Amgen | 1 | $30 |
| Viiv Healthcare Company | 2 | $30 |
| Lilly USA, LLC | 1 | $15 |
| Novartis | 1 | $13 |
| Chiesi USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$16,514
- SAPIEN 3 Ultra RESILIA$3,787
- COREVALVE EVOLUT R$2,026
- NAEOTOM Alpha$1,366
- Artis icono floor$1,145
- syngo dynamics$1,097
- ARTIS icono biplane$707
- STARCLOSE SE$525
- TRICLIP$500
- Impella$439
- EVOQUE$432
- Indigo System$384
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$353
- COROFLOW$329
- Optis Coronary Imaging System$262
- PASCAL$253
- FFRct$225
- Artis pheno$187
- 3F$182
- Vascular Lithotripsy$173
How this compares
$57,636 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 133 | $148,347 |
| Repatha SureclickEvolocumab | 63 | $72,839 |
| FarxigaDapagliflozin Propanediol | 52 | $51,667 |
| EntrestoSacubitril/Valsartan | 44 | $48,696 |
| JardianceEmpagliflozin | 25 | $36,718 |
| XareltoRivaroxaban | 20 | $25,394 |
| MounjaroTirzepatide | 17 | $17,430 |
| Bumetanide | 83 | $3,904 |
| Rosuvastatin Calcium | 204 | $3,816 |
| Metoprolol Succinate | 214 | $2,926 |
| Atorvastatin Calcium | 249 | $2,919 |
| Olmesartan Medoxomil | 47 | $2,021 |
| Nifedipine ErNifedipine | 64 | $1,883 |
| Ezetimibe | 84 | $1,732 |
| Carvedilol | 155 | $1,584 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $13 | $48,69644 claims |
| Johnson & JohnsonXarelto | $123 | $25,39420 claims |
| Lilly USA, LLCMounjaro | $15 | $17,43017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Los Angeles
- Cathleen Bairey-MerzLos Angeles$1.2M
- Karol WatsonLos Angeles$553K
- Jamil AboulhosnLos Angeles$423K
- Darren BermanLos Angeles$392K
- Arash NayeriLos Angeles$281K
- Gregg FonarowLos Angeles$260K
- Martha GulatiLos Angeles$141K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.